Mechanisms of Tubulointerstitial Injury in the Kidney: Final Common Pathways to End-stage Renal Failure

Masaomi NANGAKU

Abstract

There are many different glomerular disorders, including glomerulonephritis, diabetic nephropathy, and hypertensive nephrosclerosis. However, once glomerular damage reaches a certain threshold, the progression of renal disease is consistent and irreversible. Recent studies emphasized the crucial role of tubulointerstitial injury as a mediator of progression of kidney disease. One common mechanism that leads to renal failure via tubulointerstitial injury is massive proteinuria. Accumulating evidence suggests critical effects of filtered macromolecules on tubular cells, including lysosomal rupture, energy depletion, and tubular injury directly induced by specific components such as complement components. Another common mechanism is chronic hypoxia in the tubulointerstitium. Tubulointerstitial damage results in the loss of peritubular capillaries, impairing blood flow delivery. Interstitial fibrosis also impairs oxygen diffusion and supply to tubular cells. This induces chronic hypoxia in this compartment, rendering a vicious cycle. Development of novel therapeutic approaches against these final common pathways will enable us to target any types of renal disease.

(Key words: proteinuria, hypoxia, complement, kidney failure)

One Final Common Pathway, Proteinuria-induced Tubular Damage

One important mechanism that leads to eventual kidney failure via tubulointerstitial injury is massive proteinuria. While proteinuria had been considered merely a marker of glomerular damage, many studies indicate proteinuria as a cause of progression of renal injury (11).

A cohort of mass screening including a total of 107,192 subjects performed by Iseki and colleagues revealed that proteinuria was the most potent predictor of end-stage renal disease (ESRD) with an adjusted odds ratio of 14.9 (12). Large scale prospective studies including the MDRD study and the REIN study also established the relationship between proteinuria and progressive renal disease (13, 14). Systematic analyses of these studies revealed that greater urine protein excretion predicted a faster decline in GFR (15, 16). Furthermore, recent analysis on the data of the REIN study revealed that short-term changes in proteinuria and the actual levels of residual proteinuria reliably predicted long-term disease progression, regardless of blood pressure control and treatment randomization (17). Multivariate analysis of the RENAAAL study also demonstrated that proteinuria was an
independent risk factor that predicts renal outcomes in type 2 diabetic patients with nephropathy (18).

Animal models with heavy proteinuria, a BSA overload model (19) and adriamycin nephrosis (20), show a large number of apoptotic cells in the tubulointerstitial compartment. Theoretically apoptosis of tubular cells leads to the formation of atrophic tubules and eventually generates atubular glomeruli. This speculation was confirmed by careful pathological analysis of animal models of progressive kidney failure with massive proteinuria, 5/6 nephrectomy (21) and uninephrectomized Heymann nephritis (22), showing that tubulointerstitial damage associated with proteinuria results in the formation of atubular glomeruli and interstitial fibrosis. Recent studies using stereologic methods on human biopsy samples revealed an increase in the number of atrophic tubules and the fractional volume of cortical interstitium in proteinuric diabetic nephropathy patients (23). A relationship between proteinuria and tubulointerstitial damage was also demonstrated in studies examining 78 biopsy samples of patients with membranous nephropathy (24).

More detailed analyses of animal models and human kidney biopsy samples revealed intracellular events induced by proteinuria. Proteinuria may contribute to tubulointerstitial damage by activation of transcriptional factors (AP-1 and NF-kB) (25) and upregulation of various proinflammatory and profibrotic genes (26). Inhibition of NF-kB improved tubulointerstitial injury in adriamycin nephrosis rats (27).

Proteinuria is also associated with the transdifferentiation of tubular cells into myofibroblasts. This phenotypic change is called “epithelial to mesenchymal transformation”, and is believed to be a crucial step in fibrosis of the kidney. Two independent studies demonstrated transdifferentiation of tubular cells in the proteinuric phase of a remnant kidney model (28, 29).

All these studies showed that proteinuria activates and/or damages tubular and interstitial cells, leading to eventual kidney failure.

What Kind of Proteinuria is Harmful?

While patients with minimal change nephritic syndrome (MCNS) excrete a huge amount of protein in urine, they do not develop either tubulointerstitial damage or chronic renal failure. However, two characteristics of proteinuria in MCNS should be noted. Proteinuria of MCNS is highly selective, and patients with MCNS respond to steroid treatment, which means a relatively short duration of proteinuria in MCNS. Clinical data suggests that protracted and non-selective proteinuria induces tubulointerstitial injury and eventual kidney failure (30, 31). In patients with membranous nephropathy, IgA nephropathy, and focal segmental glomerulosclerosis, poor selectivity is significantly correlated with the severity of the tubulointerstitial damage and poor outcome (32–35).

Mechanisms of Tubulointerstitial Damage by Proteinuria

The next question is the mechanisms by which proteinuria results in tubular and interstitial damage. The mechanisms by which increased urinary protein concentrations lead to nephrotoxic injury are certain to be multifactorial and involve complex interactions between numerous pathways of cellular damage. Obstruction of tubular lumen by casts and obliteration of the tubular neck by glomerular tuft adhesions may contribute to tubulointerstitial damage by proteinuria. However, accumulating evidence emphasizes direct effects of filtered macromolecules on tubular cells (Fig. 2).

One hypothesis is that excess delivery of protein damages tubular cells in a non-specific manner and leads to tubulointerstitial injury (36–38). Reabsorption of excessive quantities of protein overloads the lysosomal pathways in the tubular cells, leading to eventual lysosomal rupture. This idea is appealing, but lacks experimental support. Excessive metabolic demands result in energy depletion. This hypothesis is also controversial because the metabolic work of protein reabsorption can be relatively modest compared with the amount of energy required to absorb other substrates such as sodium, glucose, and bicarbonate (39).

Various components in the proteinuric urine may damage tubular cells directly. These include growth factors, transferrin, albumin, albumin-bound fatty acids, and complement components. Toxic effects of these specific components are the focus of current investigation. Complement components in the proteinuric urine are believed to play an especially crucial role, and this topic is discussed in a separate section.

Albumin is one of the major components in proteinuric urine. Albumin stimulates cultured proximal tubules to express cytokines and chemokines via reactive oxygen species generation (40, 41).
Matsuo’s group, who showed that blockade of MCP-1 in a proteinuric BSA overload model attenuated tubulointerstitial injury (42). However, recent studies emphasized a role of albumin-bound fatty acids rather than albumin itself in mediating tubulointerstitial injury. Kamijo from Kimura’s group demonstrated an important role of albumin-bound fatty acids in her studies employing a BSA overload model with fatty acid depleted and fatty acid repleted albumin (43). Arici from Brunskill’s group showed that albumin-bound fatty acids stimulate PPAR and subsequently induce apoptosis in a dose-dependent manner in cultured proximal tubular cells (44).

**Activation of Complement Components in Proteinuric Urine**

Protein overload in tubular cells is associated with ammonium production. Complement component C3 modified by ammonia is called amidated C3, and amidated C3 forms the alternative pathway convertase of the complement cascade. Preferential secretion of ammonia into the tubular lumen leads to inappropriate activation of the alternative pathway at the brush border in proteinuric conditions.

Studies utilizing rats with remnant kidneys localized C3 staining in the brush border or within the cytoplasm at sites of high protein reabsorption, and C3 deposition in this model was ameliorated by reduction of proteinuria with ACE inhibitor (45, 46). Matsuo’s group performed animal experiments to clarify functional roles of complement components in proteinuric urine (47, 48). In proteinuric animals, pharmacological complement depletion improved tubulointerstitial injury. Matsuo’s group also demonstrated complement activation products in urine of patients with various glomerular diseases (49). The degree of intratubular complement activation correlated with the level of non-selective proteinuria.

We also demonstrated a crucial role of complement components, especially C5b-9, in proteinuric urine in tubulointerstitial injury induced by proteinuria. To elucidate roles of complement in proteinuric urine, we induced puromycin nephrosis and a remnant kidney model in genetically C6 deficient rats. While C6 deficient rats can produce inflammatory mediators such as C3a and C5a, they can not generate C5b-9, the terminal complex of the complement cascade. We observed that massive proteinuria induced tubulointerstitial injury associated with a marked deposition of C5b-9 on the apical membrane of proximal tubular cells in complement sufficient rats. In contrast, the tubulointerstitial damage was less severe in rats without C5b-9 formation (50, 51).

Hosts are endowed with endogenous complement regulatory proteins to protect themselves against inappropriate complement activation (52). We also demonstrated protective effects of an endogenous complement regulatory protein (Crry) in tubules against the harmful effects of tubular complement activation in the setting of massive proteinuria utilizing in vivo antisense approaches (53).

Thus, intraluminal activation of the terminal complement cascade leading to the formation of the C5b-9 membrane attack complex is a crucial mediator of tubulointerstitial damage and progressive renal failure in proteinuric renal diseases irrespective of the type of primary glomerular injury.

**Another Final Common Pathway, Chronic Hypoxia**

In some human diseases such as hypertensive nephrosclerosis, we rarely see massive proteinuria. But the patients develop tubulointerstitial damage and eventual kidney failure. This can be explained by another common pathway, chronic ischemic damage in the tubulointerstitium (54–56).

Despite a high overall oxygen supply, the tissue oxygen tension in the kidney is comparatively low due to shunt diffusion of oxygen between arterial and venous vessels that run in parallel in close contact. Oxygen tension in the renal medulla is continuously below 10 mmHg, while oxygen tension in the renal cortex is more variable, with an average PO2 of around 30 mmHg. However, the oxygen concentration in the cortex decreases dramatically in accordance with changes in renal perfusion while the oxygen concentration in the medulla is relatively preserved (57). Thus, the kidney is rather sensitive to changes in oxygen delivery. While this sensitivity is reflected by the ability of the kidney to adjust the production of EPO to changes in oxygen supply, it also renders the kidney prone to hypoxic injury.

Chronic ischemia in the tubulointerstitium can occur via several mechanisms such as intrarenal vasoconstriction (secondary to local activation of renin-angiotensin system or loss of vasodilatory nitric oxide) or structural lesions that impair blood flow delivery (Fig. 3). Impairment of the glomerular capillary bed, as it occurs in glomerulosclerosis, auto-

---

**Figure 2. Schematic view of mechanisms of proteinuria-induced tubulointerstitial injury.** Although proteinuria damages tubular cells via various mechanisms, accumulating evidence emphasizes crucial roles of direct effects of components in proteinuric urine, such as complement components.
matically impairs peritubular perfusion and thus tubular oxygen supply. Tubulointerstitial damage also results in the loss of peritubular capillaries in association with a decrease in blood flow delivery to the corresponding region. Furthermore, interstitial fibrosis impairs tubular oxygen supply because the size of the interstitial compartment determines diffusion distance between peritubular capillaries and tubular cells. These mechanisms induce chronic hypoxia in this compartment, rendering a vicious cycle.

**Loss of Peritubular Capillaries in Chronic Renal Disease**

Histological studies of human kidneys confirmed that peritubular capillary loss is correlated with interstitial fibrosis and tubular atrophy (58, 59). The significance of peritubular capillary damage, with subsequent tissue hypoxia and ischemia, has been emphasized by recent findings in animal models. Ohashi et al suggested an important role of peritubular capillary disruption in the development of renal disease and in the impairment of renal function in an anti-GBM nephritis model in Wistar Kyoto rats (60). Statistical analysis of this model revealed significant correlation between the peritubular capillary number and indicators of renal function.

We performed blockade of nitric oxide as a potent vasodilator and platelet inhibitory factor in our thrombotic microangiopathy model, and demonstrated that inhibition of eNOS markedly exacerbated the tubulointerstitial injury (61). We also studied genetically engineered rats with or without expression of endothelin receptor type B (62). This receptor is known to mediate vasodilatory and proliferative effects of endothelin. When we induced thrombotic microangiopathy in these rats, rats without endothelin receptor type B developed more severe kidney damage with loss of peritubular capillaries and deterioration of renal function.

The remnant kidney model was associated with progressive capillary loss and renal scarring. Kang from Johnson’s group showed that the loss of capillaries is correlated with a loss of VEGF in the kidney, conditions that favor endothelial cell loss and impaired angiogenesis (63). A reduction in the peritubular capillary density was also observed after severe ischemic insult, resulting in a persistent reduction in PO2 and progression of renal failure (64, 65).

All these experimental data suggest that the maintenance of the microvasculature is critical for the prevention of progression of kidney disease.

**Tubulointerstitial Hypoxia in Chronic Renal Disease**

In pigs with hypercholesterolemic diets and/or renal artery stenosis, low cortical perfusion demonstrated by electron-beam computed tomography was associated with renal fibrosis, tissue oxidative stress, and reduction in GFR (66). Matsumoto from our group showed hypoxia in the tubulointerstitial compartment in a model of chronic progressive glomerulonephritis in rats (Matsumoto M, Nangaku M. manuscript in preparation). Furthermore, we also demonstrated that hypoxia in the tubulointerstitium precedes histological damage in the corresponding compartment in a chronic kidney failure model (Manotham K, Nangaku M. manuscript in preparation).

Considering the role of ischemia in tubulointerstitial injury, one may wonder whether anemia in kidney disease can accelerate the decline in renal function. The retrospective multivariate logistic analyses of 71,802 subjects in Japan showed that anemia was an independent risk factor of end-stage renal disease (ESRD) (67). Anemia also turned out to be an independent risk factor that significantly predicted doubling of serum creatinine or ESRD in patients with type 2 diabetes in whom blood pressure was controlled (18).

**Mechanisms of Tubulointerstitial Injury by Hypoxia**

Mechanisms of tubulointerstitial damage induced by hypoxia are multifactorial. Hypoxia can activate fibroblasts, change extracellular matrix metabolism of resident renal cells, and lead to eventual fibrogenesis (68–70). Furthermore, Manotham from our group showed that mild hypoxia can induce transdifferentiation of cultured tubular cells into myofibroblasts (71). Transdifferentiation of tubular cells into myofibroblasts in a remnant kidney model was demonstrated as described above (28, 29), and it was proposed that proteinuria might play a role in this transformation. However, the phenotypic transformation in this model occurred in a relative late stage, suggesting a possible involvement of chronic hypoxia in addition to proteinuria in transdifferentia-
tion of tubular cells *in vivo*. A vicious cycle exists with hypoxia promoting interstitial fibrosis and increased matrix deposition, in turn further impairing peritubular blood flow and oxygen supply.

Renal tubular cells subjected to hypoxia have profound functional deficits of their mitochondria and persistent energy deficits (72). Tanaka from our group recently demonstrated that hypoxia induces apoptosis of renal tubular and endothelial cells via the mitochondrial pathways (73, 74). Histological analysis of a murine model confirmed that hypoxia induces apoptosis of renal tubular cells with tubular atrophy *in vivo* (75).

These studies clarified the crucial roles of chronic ischemia due to derangement of capillaries as a mediator of progression of end-stage renal disease.

**Treatment Targeting Proteinuric Tubulointerstitial Damage**

Understanding of mechanisms of tubulointerstitial injury helps us to develop novel therapeutic approaches against chronic renal failure. ACEIs and ARBs are now the golden standard of therapies against proteinuric renal disease. Renoprotective effects of these reagents had been attributed to amelioration of intraglomerular hypertension. However, recent studies demonstrated that inhibition of RAS improves the molecular mechanisms to retain glomerular permeability and reduces the amount of proteinuria. ACEIs and ARBs induce redistribution of the molecules in the slit diaphragm (76, 77), and improve selectivity of proteinuria in patients with glomerular diseases (78, 79). Large scale clinical trials and a meta analysis confirmed the benefits of ACEIs against a variety of renal diseases with their antiproteinuric effects (14, 80, 81). Furthermore, recent studies demonstrated that the greater beneficial effect of ACEIs in renal disease patients with higher baseline proteinuria could be explained by the greater antiproteinuric effects in these patients (82). Thus, one of the protective mechanisms of ACEIs and ARBs is the reduction of the amount of proteinuria.

However, these drugs do not completely inhibit the progression of chronic renal disease. Therapeutic approaches against specific components in proteinuric urine may have additive beneficial effects. As amelioration of inappropriate complement activation retards progression of chronic proteinuric renal disease in animals, the potential of using complement regulators to modify renal disease exists not just in immunological kidney disease but possibly also in chronic non-immunological proteinuric renal injury (83).

**Treatment Targeting Hypoxic Tubulointerstitial Damage**

As anemia is a risk factor for renal failure, correction of anemia by EPO and the subsequent improvement in oxygenation of the kidney should theoretically retard progression of renal failure. One retrospective study (84) and two prospective studies (85, 86) suggested that improvement of anemia by treatment with EPO delayed the progression of renal failure.

While an increase in the number of erythrocytes by EPO improves oxygen delivery to organs, cells can adjust to hypoxic conditions by various mechanisms.

VEGF treatment reduces fibrosis and stabilizes renal function in the remnant kidney model (87). Administration of VEGF also restores the number of peritubular capillaries and protects the kidney in the thrombotic microangiopathy model (88, 89). These beneficial effects of VEGF were probably mediated by preservation of the capillary endothelium and were associated with partial reversal of the impaired angiogenesis. However, because the formation of a functionally intact microvasculature requires coordinated activation of several genes, vessels induced by overexpression of a single gene such as VEGF may be leaky, immature, or irregular. Recent studies by Floge’s group demonstrated aggravation of mesangial injury by treatment with VEGF in anti-Thy1 nephritis, cautioning against therapeutic approaches utilizing VEGF (90). It is desirable to activate a “master gene” switch that results in a broad and coordinated downstream reaction to protect tissues against hypoxia.

One of the most important factors in the cellular response to hypoxia is hypoxia-inducible factor, HIF (91). HIF binds to the hypoxia responsive element in the cis-regulatory regions of its target genes, and transcriptionally activates genes encoding proteins that mediate adaptive responses to reduced oxygen availability. Under normoxic conditions, the binding of pVHL to HIF1-alpha, which is hydroxylated on conserved prolyl residues, directs the polyubiquitination and proteasomal degradation of the latter. Under hypoxic conditions, the prolyl hydroxylase enzyme cannot hydroxylate HIF, and therefore HIF is not recognized by pVHL. As a result, HIF accumulates in the cell and is available to activate transcription. Therefore, stimulation of HIF-1 signaling can be theoretically more effective in ischemic states because it can induce expression of a variety of oxygen-regulated and renoprotective genes.

Prolyl hydroxylase inhibitors are the focus of recent studies as a novel strategy to stabilize HIF, and a variety of new compounds are now being developed (92). Local injection of these inhibitors increased invasion of highly vascularized tissue in a sponge model of angiogenesis (93). Polypeptides containing the HIF prolyl hydroxylation motifs fused to a nuclear translocation signal were shown to compete with endogenous HIF for its degradative pathway, resulting in HIF stabilization and induction of angiogenesis *in vivo* (94). In models such as hindlimb ischemia, injection of DNA expressing a constitutively active fusion protein containing the N-terminal half of HIF-1alpha and VP16 was more effective than a VEGF-expressing vector in restoring blood flow (95–97).

The prolyl hydroxylation requires iron as a cofactor, and this requirement explains the hypoxia-mimetic effects of iron chelators such as deferoxamine and iron antagonists such as
cobalt chloride. Cobalt chloride activates the HIF pathway not only by antagonizing this reaction but also by inhibition of the interaction between HIF-alpha and von Hippel-Lindau protein (98). We recently demonstrated renoprotective effects of stimulation of HIF-1 signaling utilizing cobaltous chloride administration in an ischemic model of renal injury (99). Administration of cobalt induced up-regulation of HIF-regulated genes, such as VEGF and EPO, and subsequently improved the tubulointerstitial damage induced by hypoxia.

**Summary and Conclusion**

Tubulointerstitial injury is a final common pathway leading to end-stage renal failure. This is mediated by massive proteinuria containing a large amount of complement components and chronic hypoxia with loss of peritubular capillaries in the tubulointerstitium. Relative contributions of these pathways may vary among different clinical entities and individual cases (Fig. 4). Further studies are awaited to develop powerful therapeutic approaches against these final common pathways, which can target any types of renal disease.

**Acknowledgments**: The author is very grateful to Dr. William G. Couser (University of Washington, Seattle, WA), Dr. Kiyoshi Kurokawa (Tokai University, Isehara, Japan), and Dr. Toshiro Fujita (University of Tokyo, Tokyo, Japan) for their generous support. The author is also grateful to Drs. Richard J. Johnson (University of Florida, Gainesville, FL), Reiko Inagi (Tokai University, Isehara, Japan), Toshio Miyata (University of Tokai, Isehara, Japan), and Stuart J. Shankland (University of Washington, Seattle, WA) for their continuous support. Particular thanks are due to my friends and colleagues: Takamoto Ohse, Tetsuhiro Tanaka, Ichiro Kojima, Makiko Matsumoto, Jing Shao, Krissanapong Manotham. The author would like to acknowledge research grants from the Japanese Ministry of Health, Labour and Welfare and NOVARTIS Foundation (Japan) for the Promotion of Science.

**References**

5) Striker GE, Schainuck LI, Cutler RE, Benditt EP. Structural-functional...


46) Abbate M, Zojca C, Corna D, Capitiano M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered...


86) Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal